Research guide to BPC-157 — gut healing, tight junction restoration, tendon repair and more. Preclinical evidence reviewed. For Research Use Only.
May 31, 2026 | 10 min read
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide compound developed by Eli Lilly. It is a triple receptor agonist — simultaneously activating three metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor.
No currently approved drug targets all three receptors at once. This multi-receptor mechanism is what makes Retatrutide one of the most discussed and researched compounds in metabolic science today.
GLP-1 Receptor: Suppresses appetite, stimulates insulin secretion in a glucose-dependent manner, and slows gastric emptying. This is the same receptor targeted by semaglutide (Ozempic/Wegovy).
GIP Receptor: Enhances fat metabolism, potentiates insulin secretion, and boosts the effectiveness of GLP-1 signaling. This receptor is also targeted by tirzepatide (Mounjaro/Zepbound).
Glucagon Receptor: Drives thermogenesis and energy expenditure — increasing calorie burn and broadening the metabolic reach of the compound beyond appetite suppression alone. This is the key differentiator that sets Retatrutide apart from all existing approved therapies.
